Lonza, BioWa Sign Licensing Agreement - - BioPharm International

ADVERTISEMENT

Lonza, BioWa Sign Licensing Agreement



BioWa and Lonza have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which  MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System.  The GS System includes Lonza’s host cell line, CHOK1SV.  Potelligent Technology is designed to improve the potency and efficacy of therapeutic antibodies by improving antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.

MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent Technology.   Today’s agreement incorporates Lonza’s technology to the existing Potelligent Technology.

Source: Lonza

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here